kentucky semaglutide stomach paralysis class action Novo Nordisk sues Eli Lilly for false advertising over weight loss drug comparisons. Get the details semaglutide manufacturers stomach paralysis lawsuit

The massive weight loss many users experience, sometimes 15-20% of body weight, makes these peptides impossible to ignore

DharRSinghSTalwarDMohanMTripathiSSwarnakarRet al

When both receptor systems are activated, the cumulative impact on appetite and food thoughts might exceed what GLP-1 alone produces

The litigation covers NAION claims tied to multiple GLP-1 medications, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound

They will likely want to: Review your complete medication list to identify potential interactions with other drugs you are taking Assess your diabetes status and current glycaemic control if you have type 2 diabetes Evaluate your tolerance of Wegovy to date, particularly regarding gastrointestinal side effects Discuss your treatment goals and whether berberine is likely to provide meaningful additional benefit Establish a monitoring plan if you proceed with the combination For people with type 2 diabetes and existing diabetic retinopathy, healthcare professionals may recommend appropriate eye monitoring when starting treatments that can rapidly improve glycaemic control, as this can sometimes temporarily worsen retinopathy